IRRITABLE BOWEL SYNDROME AND BASAL SERUM TRYPTASE: THE CORRELATION BETWEEN SUBTYPE, SEVERITY AND COMORBIDITIES. A PILOT STUDY

• DOI: 10.17235/reed.2021.7697/2020
• Publication Date: 2021-02-09T07:55:40Z
• Authors: Constanza Ciriza ...; Isabel Castel de ...; Fernando Canga Ro...; María del Carmen ...; Natividad de las ...; Enrique Rey Díaz-...
• Keywords: Bloating; Tryptase; Functional gastrointestinal disorder

IntroductionActivation of mast cells causes alteration in epithelial and neuromuscular function, is involved visceral hypersensitivity dysmotility gastrointestinal functional disorders. ObjectivesPrimary: Evaluate differences basal serum tryptase (BST) between patients with irritable bowel syndrome (IBS) healthy controls.Secondary: BST depending on IBS subtype (diarrhea: IBS-D; constipation: IBS-C), comorbidities correlations severity quality life. Material methodsProspective control-case study (Rome IV criteria).BST was determined (ImmunoCAP-Phadia, Sweden®) Severity Score (IBSSS), pain, bloating flatulence analogue scales, life (IBSQOL) patient health status (PHQ-9) were performed.BST the primary variable achieving end-point. ResultsThirty-two patients, 21 (65.6 %) IBS-D, 11 (34.4 IBS-C 32 controls included.Mean IBSSSS: 326.6 (± 71.4), IBSQOL: 76 20.3) PHQ9: 10.2 5.9).BST 4.8 ± 2.6 4.7± (p=0.875).There no difference subtypes (4.7 2.9 IBS-D 5± 1.8 IBS-C; p =0.315) or (p=0.662).However, higher extraintestinal compared to other (p=0.029).This subgroup also has more severe (p=0.021).There correlation BST, (p=0.9260)and (p=0.3985). ConclusionBST does not discriminate controls.However, which have bloating.This finding worthy investigation.